BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Advanced Endometrial Cancer Clinical Trial

Official title:
A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma

Status Completed

Clinical Trial Summary

This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line antineoplastic treatment. Patients will receive BKM120 orally at a dose of 100 mg/day. Availability of tumor specimen (either archival tissue or a fixed fresh biopsy) is mandatory for assessment of the PI3K (Phosphatidylinositol 3 Kinase (PI3K) pathway activation status.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01289041
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	February 2011
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04574284` - A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Phase 2
Withdrawn	`NCT06046274` - GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Phase 2
Recruiting	`NCT05112991` - Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer	Phase 2
Not yet recruiting	`NCT05106127` - Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem	Phase 2
Not yet recruiting	`NCT05077215` - Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer	Phase 3
Recruiting	`NCT05481645` - Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	Phase 2